In response to a call for comment on the proposed New York Office of Cannabis Management symbol, the Doctors for Cannabis Regulation submitted a letter outlining the design flaws of the proposed symbol and recommended adopting the International Intoxicating Cannabinoid Product Symbol instead.
In a recent press release (1), Doctors for Cannabis Regulation (DFCR) published their letter sent to the New York State Cannabis Control Board (CCB) and the New York Office of Cannabis Management (OCM). “The DFCR is the global voice for physicians and other health professionals to advance the legalization and science-based regulation of cannabis,” explained the introduction. In the letter, the DFCR explained why New York should adopt the International Intoxicating Cannabinoid Product Symbol (IICPS) on all cannabis products sold in the state. In addition, 22 other cannabis organizations signed their support and three states—Montana, Vermont, and New Jersey—have already adopted the IICPS.
“The IICPS was developed through a collaboration between DFCR and ASTM International, meeting a list of requirements including being able to simply communicate a public health message of ‘Caution with Cannabis,’ using the simplest possible design to fit within an allotted space and incorporating a symbol that transcends age, language, culture, literacy, and knowledge of cannabis and the Latin alphabet,” said the DFCR in the letter (1).
The DFCR listed the following as the main flaws of the symbol proposed by the OCM (1):
More on the IICPS can be found in an article published in Cannabis Science and Technology. Last year, founder and past president of DFCR Dr. David Nathan along with product designer Eli Nathan, contributed an in-depth explanation of the formulation and implementation of the IICPS. “We present the IICPS to regulators with a simple message: This is not just the right choice as a universal symbol for cannabis products—it’s also the safe choice,” concluded the co-designers of the IICPS (2).
References
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Senate Committee has released the text of 2024 Farm Bill, with changes to hemp regulations
November 19th 2024The U.S. Senate Committee on Agriculture, Nutrition, & Forestry has introduced the Rural Prosperity and Food Security Act, which will serve as the Senate’s draft for the 2024 Farm Bill.
Ep 23, Part III: Accreditation in the Cannabis Industry with Susan Audino
October 24th 2024In Part III of this episode, host Evan Friedmann is joined by Susan Audino, PhD, founder of S.A. Audino & Associates, LLC, and co-founder of Saturn Scientific, LLC, to examine the complexities of sampling in the cannabis industry, emphasizing the need for proper sampling plans, and methods.